|
HS Code |
473582 |
| Product Name | (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester |
| Molecular Formula | C19H18BrN5O2 |
| Molecular Weight | 428.29 g/mol |
| Cas Number | 1632220-47-1 |
| Appearance | Solid |
| Purity | Typically ≥98% |
| Solubility | DMSO, Methanol |
| Storage Conditions | Store at -20°C, protected from light |
| Smiles | C1=CC=C(C=C1)COC(=O)C2CCCN2C3=NC4=CN=C(NC4=N3)NBr |
| Synonyms | None reported |
| Iupac Name | (2S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-pyrrolidinecarboxylic acid phenylmethyl ester |
| Application | Pharmaceutical intermediate; research chemical |
As an accredited (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Applications of (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester in Industrial ManufacturingAs a specialized manufacturer of advanced heterocyclic intermediates, we supply (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester to clients engaged in high-value synthesis for the pharmaceutical and biotech industries. Our production emphasizes consistent purity to meet the stringent demands of original molecule construction, particularly in the fields of oncology R&D, targeted drug conjugate manufacturing, and research-scale catalytic studies. Detailed below are key downstream applications where this intermediate plays a critical role, including associated standards, precise usage, process flow, and the types of finished products manufactured by our global customers. 1. Anticancer Drug Intermediate SynthesisThe compound serves as an essential building block in the synthesis of small molecule kinase inhibitors, primarily those developed for targeted cancer therapies. Medicinal chemists incorporate it during lead optimization and scale-up, leveraging its unique bromo-imidazopyrazine motif for further derivatization in key step transformations. It reliably supports structure-activity relationship studies, clinical candidate scale-up, and transfer into GMP-compliant production of oncology APIs. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
2. Antibody-Drug Conjugate (ADC) Payload Linker PrecursorResearchers and contract manufacturers apply this compound in the synthesis of payload-linker systems for next-generation antibody-drug conjugates. Its bromo-substituted heterocycle serves as a convenient attachment site for further linker extension, nucleophilic substitution, or bioconjugation steps, allowing precise connection to cytotoxic payloads or monoclonal antibodies under controlled conditions. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
3. Fragment-Based Drug Discovery LibrariesThe core scaffold is a preferred warhead fragment for assembling focused screening libraries used in structure-based drug design. With the correct configuration and functional groups, it supports medicinal chemistry teams in generating diversified compound libraries targeting novel binding pockets, including epigenetic enzyme inhibition and allosteric site probing. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
4. Advanced Chemical Reference Standard ProductionQuality control laboratories and regulated API producers utilize this compound as a chemical reference standard in analytical method validation, impurity profiling, and calibration for both in-process and final product testing of heterocyclic drug candidates, ensuring traceable data for regulatory submissions under international guidelines. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
|
Competitive (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
In the world of organic chemistry and drug discovery, specialized compounds matter more than people often realize. Take (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester: a mouthful for most of us, yet a structurally precise tool for anyone exploring new medicinal connections. Every piece of its name tells a story about how researchers imagine, test, and evolve molecules with the potential to make an impact.
This compound steps up with a profile that attracts professionals focused on kinase inhibitor research, structure-activity relationship exploration, and fragment-based drug design. The presence of the bromo and amino groups on the imidazopyrazine ring hints at reactivity patterns and interaction points often sought after when tuning a molecule for bioactivity. The chirality at the pyrrolidine ring (noted by the (2S) prefix) adds another layer of control over how the compound interacts with biological targets, reinforcing why it stands apart in a crowded chemical catalog.
Design doesn’t happen by accident. The selection of a benzyl ester as a protective group plays a functional role in synthetic chemistry. It can allow researchers to process a pathway that calls for deprotection at just the right phase, providing strategic flexibility. For those who have spent hours troubleshooting reactions or hunting for workable intermediates, a compound like this brings relief because of its tailored reactivity. The bromo group, for example, opens the door to cross-coupling reactions such as Suzuki or Buchwald–Hartwig couplings, both of which drive innovation in the pharmaceutical sector. The amino group on the imidazopyrazine ring sets up opportunities for derivatization, amide formation, or direct exploration of hydrogen bonding in protein-ligand studies.
Compared to more routine reagents, this model captures greater potential because the core structure blends robust chemical stability with defined reactivity. Safety and handling remain important for all chemicals, but seasoned professionals know that molecules with bromo and amino functionalities often favor stability under lab-standard conditions, making them easier to work with for both bench chemists and process development scientists.
A molecule like this doesn't just sit on a shelf for admiration. Laboratories put it to work as both a starting point for analog synthesis and a fragment for screening libraries. The combination of aromatic and heterocyclic elements broadens the scope for attaching additional groups, increasing chemical diversity, and optimizing target binding. In my own academic and industrial experiences, specialists appreciate intermediates that cut down on optimization headaches and offer low risk of unwanted side products.
Colleagues at pharmaceutical startups often talk about how early-stage screening eats up time and resources if foundational compounds don’t provide a reliable platform. This particular ester, with its defined stereochemistry, helps direct the course toward efficient lead compound development. Its unique core fits into the library design strategies favored in big pharma and curious biotech firms. The stereochemistry, aromatic groups, and halogenation let teams tackle fundamental questions about biological activity right at the start of a project, helping them decide quickly whether a path is promising or not.
In the real world, chemists trying to design inhibitors or agonists crave features that not only increase biological relevance but also facilitate synthetic modification. Lower complexity building blocks might get the job done for some explorations, but a molecule like (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester acts as both a tool and a stepping stone. Compared to smaller or less functionalized fragments, it can bring together features currently driving much of the research in molecularly targeted therapies.
Other chemical staples—a plain imidazopyrazine or a substituted pyrrolidine—don’t offer the same ready coupling capability with diverse side chains or the inviting pockets for further modification by late-stage functionalization. From my perspective, these capabilities speed up exploratory research and inspire creative chemistry, while giving researchers a shot at improved solubility or optimized pharmacokinetics when transitioning to in vivo models.
As with any purposeful compound, the foundation lies in its purity, documented stereochemistry, and a reliably communicated molecular weight. Those who’ve spent late nights poring over HPLC traces know how a reputable product saves hours in troubleshooting and checking for impurities. The molecular formula reflects the inclusion of bromine, which not only adds a unique synthetic handle but also adjusts the molecular weight in ways relevant to mass spectrometry-based detection and labeling efforts.
Long-time users point to how this kind of molecule often comes with verified analytical data: NMR reporting to confirm stereochemistry, mass spec for molecular weight confirmation, and perhaps X-ray crystallographic data for publication-grade studies. In teams I’ve worked with, this data gives peace of mind and underpins strong reproducibility. A solid audit trail reflects depth of care in sourcing and supports regulatory submissions if the project advances toward clinical studies.
Seasoned chemists understand that molecules with bulky or reactive functional groups reward careful technique in both storage and application. Product with a benzyl ester can often live at low temperatures for long-term storage, retaining both chemical integrity and viability for later phases of synthesis. More than one time, careful aliquoting and proper sealing saved projects from setbacks, especially when environmental moisture or light could introduce decomposition.
This is not a commodity or bulk chemical, so professionals treat it with the seriousness it deserves—standard PPE, careful tracking, and coordination with analytical teams to ensure every run delivers the best return. The experience of losing rare intermediates to mishandling stays on every researcher’s mind, pushing teams toward robust inventory practices and close collaboration with QC staff.
A structurally elaborate molecule like this asks for diligence in waste management and downstream impact checks. Even without acute toxicity, bromo-containing intermediates call for responsible waste handling to avoid environmental impacts. My training always included a strong emphasis on traceability and regulatory readiness; compliance teams scrutinize every bit of the supply chain, often tracing chemical footprints from bench to waste processing. This culture lowers risk, supports sustainability, and makes transitions to scale-up or process intensification smoother.
Those who navigate chemical procurement appreciate vendors who share credible batch-specific data, safety records, and handling guidance. The best professional suppliers know that research teams have to satisfy not just scientific milestones but also compliance audits, and this compound’s well-documented production pathways offer peace of mind in both respects.
A compound like (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester stands as a bridge between what’s currently possible and what researchers wish to achieve. Beyond its catalog description, it represents years of incremental progress in synthetic chemistry, analytical validation, and applied biochemistry. My colleagues in medicinal chemistry have often shared stories of how specialized building blocks, once hard to source, have unlocked rapid successions of lead series designs that would have cost months or years to make from scratch just a decade ago.
This narrative matches my own experiences where teams merge robust chemistry tools with evolving screening technologies, be it high-throughput binding assays or automated SAR optimization. Bringing a powerful intermediate to the lab bench changes the scope of possibilities, reduces reruns, and lets data guide the next question with confidence. Teams in industry and academia look for versatility, traceable production, and structures built for extension, just like what this molecular scaffold offers.
Solving the practical challenges of early drug discovery or chemical biology takes more than just smart teams—it relies on access to the right starting points. Professional suppliers who invest in producing stereochemically defined, functionally rich intermediates like this one help laboratories sidestep the frustrations of variable quality or ambiguous documentation. From firsthand experience, streamlined access to such compounds gives teams the time and space to dig into meaningful experiments, knowing supply issues or characterization mysteries won’t derail progress.
Tackling remaining issues in the space comes down to sharing best practices, investing in supplier relationships, and championing transparency in sourcing and analytical reporting. In many ways, the work done before a vial ever reaches the bench—meticulous batch records, verified COAs, open communication between buyers and technical support—ends up making as big an impact as any clever synthetic trick or screening innovation. The trust built through reliable product delivery and consistent specifications enables scientists to push their research further, with fewer roadblocks and clearer pathways to success.
Seasoned researchers often talk about the difference quality starting materials make—not just in obvious ways like yield or purity, but in the peace of mind that comes from consistent results. I’ve had students and colleagues who spent days chasing down side reactions, only to realize an under-characterized intermediate was at the root. The ability to source a thoughtfully assembled, multipurpose molecule like (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester changes the day-to-day experience from one of troubleshooting and repair to one of exploration and concrete progress.
Bridge molecules like this one highlight the power of collaboration across supplier, customer, and regulatory lines. Each time scientists can rely on a standard, well-characterized intermediate, they raise the bar for the whole industry. Returns show up both in faster project timelines and in the improved reproducibility that supports publication, patenting, and eventual clinical progress.
Chasing new medicines or molecular tools requires a toolkit built with both imagination and discipline. The role of thoughtfully designed molecules lies at this intersection. The presence of the bromo group allows for rapid expansion of chemical space using cross-coupling, while the benzyl ester brings controlled reactivity during multi-step syntheses. Researchers working with diverse chemical transformations know the importance of reliable intermediates—choices here can make or break a campaign’s success.
Every experienced synthetic chemist remembers the learning curve that comes from handling real-world compounds. From smart aliquoting to sharp attention during high-performance liquid chromatography, this work rewards both patience and reliable building blocks. I’ve seen the right intermediate shave weeks off a project or turn a stalled research avenue into a productive study. This isn’t just about convenience; it’s about shifting the limits of what science can do with the time and funding available.
Looking forward, advances in automated synthesis and AI-guided compound selection continue to raise the standards for what molecules like (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester can do for drug hunters and chemical biologists. Teams can now design, order, and deploy custom molecules on timescales that once would have sounded impossible. This intermediate reflects a future where high-value, functionally rich compounds become accessible across disciplines, driving collaboration between chemists, biologists, and data scientists.
Increasing transparency in supply chain management and raising the bar for analytical reporting have already improved access to specialty intermediates. The hope is that this trend continues, removing barriers for smaller academic groups and startups as well as established pharma companies. Each time the field levels up—through smarter production, clearer data, or tighter relationships between supplier and researcher—the prospects for discovery and real-world solutions expand.
Quality intermediates such as (2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester don’t just move research forward—they embody the best practices of an evidence-driven, innovation-minded industry. If we listen to the feedback from the bench, invest in robust analytical protocols, and share knowledge across the scientific community, the field will keep finding ways to turn today’s molecular tools into tomorrow’s breakthroughs.